EuroBioHighTech 2026

An event fully dedicated to the Health Technology Assessment for BioHighTech Innovation that will take place in the Urban Center of Trieste on the 25th September 2026.

The eleventh edition of Eurobiohightech, focusing on Science to Business, will take place within Trieste Next, an event aimed at disseminating scientific information to citizens (Science to Citizen).

As in previous editions, the day's proceedings are organized into four round tables that analyze the topic of Health Technology Assessment from four different perspectives. Two round tables address how to finance the development of BioHighTech innovation, both with predominantly public investments and with private investments aimed at supporting the industrialization and commercialization of technological innovations. The other two round tables examine solutions and/or problems related to the procurement of these same innovations with predominantly public investments by the Italian National Health Service (NHS) and/or by the health services of other countries in neighboring countries such as Austria, Croatia, and Slovenia.

Unfortunately the public sector that finances biohightech development in Italy, as well as in the Friuli Venezia Giulia region, is heavily bureaucratic, slowing down the procurement of these innovations within the National Health System. The first Eurobiohightech roundtable will address this important issue, both from the perspective of the processes used by some public bodies in the Friuli Venezia Giulia region and those illustrated by some biohightech companies active in the innovation process of healthcare technologies, including artificial intelligence.

To accelerate the procurement of biohightech and AI innovations, the aim is to begin with the promotion (and the topic of the fourth roundtable) of the joint use of clinical HTA procedures in some neighboring countries, also thanks to the implementing regulation of the European Directive on HTA (medicinal products and medical devices), which came into force in January 2025.

According to this Regulation, clinical HTA activity will be progressively strengthened with the central European collection of clinical data submitted on a drug and a medical technology in a single European country in order to rapidly obtain a European clinical assessment of the efficacy and safety of a new drug and/or a new medical technology.

One-to-one meetings and networking sessions are also planned to facilitate new collaborations between companies, investors, institutions, and researchers, as well as presentations by startups, research organizations, and financial institutions. Euro-biohightech brings together CEOs and founders of innovative companies (such as Biovalley Group S.p.A., Alifax S.r.l., Chemicare S.r.l., CoQuaLab T S.r.l., Simplifica S.r.l., Serichim S.r.l., SINDREL MEDTECH, AIXELERATE S.r.l., and Unicorn Apulia) that present advanced solutions in biotechnology, diagnostics, pharmacology, and AI applied to healthcare and are poised for commercial and industrial expansion due to their high growth potential.